Significance: A noninvasive intranasal (i.n.) influenza vaccine can induce mucosal immune responses in respiratory tracts, preventing infection at the portal of virus entry. However, the absence of appropriate mucosal adjuvants at present hinders the development of such a vaccine. Here, we developed polyethyleneimine-functionalized two-dimensional graphene oxide nanoparticles (GP) that showed high antigen-loading capacities and superior immunoenhancing properties. Robust and broadly reactive immune responses were induced with i.n. immunization with GP-HA nanoparticles, conferring protection against homologous and heterologous viruses. With versatility and flexibility, GP nanoparticles can be easily adapted for constructing mucosal vaccines of different respiratory pathogens.
[ 18 F]MFTMT was internalized only by S. aureus in vitro . In vivo imaging showed that the tracer also accumulated in S. aureus , E. coli in vivo and non-infectious inflammatory tissue, and we found SGLT1 caused this non-specific accumulation.
We synthesized hybrid thiomaltodextrins targeting malE of Escherichia coli ( E. coli ). They did not bind to malE of Staphylococcus aureus but bound to malE of E. coli and are likely internalized by E. coli .